Literature DB >> 32453208

Food and Drug Administration Safety Communication on the Use of Transvaginal Mesh in Pelvic Organ Prolapse Repair Surgery: The Impact of Social Determinants of Health.

Jialin Mao1, Bilal Chughtai2, Said Ibrahim1, Art Sedrakyan1.   

Abstract

OBJECTIVE: This study was to examine the impact of the July 2011 Food and Drug Administration (FDA) safety communication on the use of transvaginal mesh in pelvic organ prolapse (POP) repair by patients' race and ethnicity.
METHODS: We conducted an observational cohort study of women undergoing POP repairs in 2008 to 2015 in New York State. We examined the changes in transvaginal mesh use in POP repairs before and after the FDA communication by patients' race and ethnicity. Piecewise logistic regression models were used to assess the trends of mesh use, adjusting for patient characteristics. We performed a subgroup analysis of the trends of transvaginal mesh use by racial groups, stratifying by patients' neighborhood socioeconomic status.
RESULTS: We included 49,848 women (78% white, 7% black, and 15% Hispanic) with an average ± SD age of 60.2 ± 13.0 years. After the safety communication, the use of transvaginal mesh in POP repairs decreased among white women (odds ratio [OR], 0.45; 95% confidence interval [CI], 0.41-0.50) and African Americans (OR, 0.48; 95% CI, 0.35-0.67) but remained stable among Hispanic women (OR, 0.88; 95% CI, 0.70-1.11). Only in the subgroup of patients from high-income areas, there was a trend toward decreasing mesh use among Hispanic patients after 2011 (OR, 0.71; 95% CI, 0.49-1.04).
CONCLUSIONS: The communications related to the safety of transvaginal mesh did not have an equal impact across racial groups. Mesh use decreased among white and African American women but not among Hispanic women after the 2011 FDA safety communication. Particular attention is warranted for patients from disadvantaged groups, especially low-income minorities, when disseminating medical device safety messages.
Copyright © 2020 American Urogynecologic Society. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 32453208      PMCID: PMC7679269          DOI: 10.1097/SPV.0000000000000863

Source DB:  PubMed          Journal:  Female Pelvic Med Reconstr Surg        ISSN: 2151-8378            Impact factor:   1.913


  11 in total

1.  Responding to an FDA warning--geographic variation in the use of rosiglitazone.

Authors:  Nilay D Shah; Victor M Montori; Harlan M Krumholz; Karen Tu; G Caleb Alexander; Cynthia A Jackevicius
Journal:  N Engl J Med       Date:  2010-11-17       Impact factor: 91.245

Review 2.  Social conditions as fundamental causes of health inequalities: theory, evidence, and policy implications.

Authors:  Jo C Phelan; Bruce G Link; Parisa Tehranifar
Journal:  J Health Soc Behav       Date:  2010

3.  Regulatory Warnings and Use of Surgical Mesh in Pelvic Organ Prolapse.

Authors:  Art Sedrakyan; Bilal Chughtai; Jialin Mao
Journal:  JAMA Intern Med       Date:  2016-02       Impact factor: 21.873

4.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

5.  Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study.

Authors:  Joanne R Morling; David A McAllister; Wael Agur; Colin M Fischbacher; Cathryn M A Glazener; Karen Guerrero; Leanne Hopkins; Rachael Wood
Journal:  Lancet       Date:  2016-12-21       Impact factor: 79.321

6.  Characterizing declines in pediatric antidepressant use after new risk disclosures.

Authors:  Susan H Busch; Richard G Frank; Andres Martin; Colleen L Barry
Journal:  Med Care Res Rev       Date:  2010-07-30       Impact factor: 3.929

7.  Rate of Pelvic Organ Prolapse Surgery Among Privately Insured Women in the United States, 2010-2013.

Authors:  Anne G Sammarco; Carolyn W Swenson; Neil S Kamdar; Emily K Kobernik; John O L DeLancey; Brahmajee Nallamothu; Daniel M Morgan
Journal:  Obstet Gynecol       Date:  2018-03       Impact factor: 7.661

8.  Differences in diffusion of FDA antidepressant risk warnings across racial-ethnic groups.

Authors:  Andrea Elizabeth DePetris; Benjamin L Cook
Journal:  Psychiatr Serv       Date:  2013-05-01       Impact factor: 3.084

9.  Long-term Device Outcomes of Mesh Implants in Pelvic Organ Prolapse Repairs.

Authors:  Bilal Chughtai; Jialin Mao; Tirsit S Asfaw; Carl Heneghan; Charles R Rardin; Art Sedrakyan
Journal:  Obstet Gynecol       Date:  2020-03       Impact factor: 7.661

10.  Use and risks of surgical mesh for pelvic organ prolapse surgery in women in New York state: population based cohort study.

Authors:  Bilal Chughtai; Jialin Mao; Jessica Buck; Steven Kaplan; Art Sedrakyan
Journal:  BMJ       Date:  2015-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.